Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...
Main Authors: | Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BMJ Publishing Group
2016
|
Similar Items
-
Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
by: Griesenbach, U, et al.
Published: (2016) -
Moving lentiviral-based gene therapy into a first-in-man CF trial
by: Griesenbach, D, et al.
Published: (2015) -
Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
by: Hyde, S, et al.
Published: (2015) -
Towards a first-in-human trial with a pseudotyped lentivirus
by: Alton, EW, et al.
Published: (2020) -
Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
by: McLachlan, G, et al.
Published: (2011)